Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Neoplasms
  • Oxonic Acid
  • Pyridines
  • Tegafur

abstract

  • The recommended dose of S-1 in chemotherapy-naive or minimally chemotherapy-exposed patients is 40 mg/m(2) bid on 28 consecutive days, every 5 weeks. In heavily pretreated patients, the recommended dose is 35 mg/m(2) bid. Phase II trials are warranted in tumors known to be responsive to 5-FU treatment.

publication date

  • January 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2000.18.14.2772

PubMed ID

  • 10894878

Additional Document Info

start page

  • 2772

end page

  • 9

volume

  • 18

number

  • 14